Watson's GELNIQUE™ (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder

Corona, CA, January 27, 2009 - Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE™ (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year.More on FDA Approval of Gelnique from Watson Pharmaceuticals

NewsInfusion | May 4, 2009

Tags:. .wpi. .overactive. .incontinence. .urinary. .bladder